Clinical Scorecard: Could Omics Improve Fabry Disease Diagnosis?

At a Glance

Key Highlights

• Multi-omics research may identify biomarkers for Fabry disease diagnosis and monitoring.
• Alpha-galactosidase A activity and Lyso-Gb3 levels are currently used but have limitations.
• Transcriptomics, proteomics, and metabolomics could supplement existing diagnostic approaches.
• Kidney and cardiac involvement are significant areas of focus in Fabry disease research.
• Routine multi-omics testing is not yet supported due to insufficient evidence and practical barriers.

Guideline-Based Recommendations

Diagnosis

• Combine clinical and family history with enzyme activity, Gb3 or Lyso-Gb3 measurements, and genetic testing.

Management

• Monitor organ involvement, particularly in the kidneys and heart.

Monitoring & Follow-up

• Consider molecular profiles alongside traditional diagnostic methods.

Risks

• Renal damage may progress to kidney failure; cardiac complications may arise.

Patient & Prescribing Data

Patients with Fabry disease, especially those with heterozygous variants.

Current treatments may not fully address the complexities of organ involvement.

Clinical Best Practices

• Utilize a combination of biochemical and genetic testing for comprehensive diagnosis.
• Stay updated on emerging biomarkers from multi-omics studies.

Related Resources & Content

• Genes & Diseases Review